Life’s Crucial 9, Genetic Susceptibility, and the Risk of Atrial Fibrillation: A Prospective Study in the UK Biobank Cohort
Canadian Journal of Cardiology · 2026
DOI: 10.1016/j.cjca.2025.07.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Cardiology, 2026. Verfasst von Jianing Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou, P.R. China; The Fourth Affiliat…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Genetic Predisposition to Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: To date, the association between Life's Crucial 9 (LC9) and incidence of atrial fibrillation (AF) has not been explored. This study aimed to investigate the association between LC9 and the incidence of AF and evaluate the potential role of genetic risk. METHODS: LC9 consists of 9 elements categorized as low, medium, and high cardiovascular health (CVH). Polygenic risk scores (PRSs) were categorized as low, medium, or high. A Cox proportional hazards regression model was used to determine the association between LC9 and incidence of AF. The combined effects and interactions between LC9 and AF PRS on incidence of AF were also examined. RESULTS: During the median follow-up of 12.87 years, 11,141 patients developed AF. Moderate CVH (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.70, 0.79) and high CVH (HR, 0.66; 95% CI, 0.62, 0.71) were associated with a reduced risk of AF, respectively, compared with those with low CVH. Individuals with a high CVH and low PRS exhibited the lowest risk of AF compared with those with low CVH and high PRS (HR, 0.55; 95% CI, 0.47, 0.64). Additive interactions between low-to-moderate CVH and high PRS were found (relative excess risk caused by interaction: 95% CI, 1.45 [0.75, 2.15] and 0.60 [0.28, 0.92]; attributable proportion caused by interaction: 95% CI, 0.25 [0.15, 0.35] and 0.14 [0.06, 0.21], respectively). CONCLUSIONS: Higher LC9 scores were associated with a decreased risk of AF. Adherence to the LC9 guidelines may help reduce the incidence of AF, regardless of genetic risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou, P.R. China; The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou, P.R. China.
- The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou, P.R. China; The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Electronic…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, J., Li, G., Ma, Z., Sun, Z., Shi, Y., Lou, Z., Zhao, H., Sun, M., Wang, Y., Han, Q., Jiang, M., & Shen, Y. (2026). Life’s Crucial 9, Genetic Susceptibility, and the Risk of Atrial Fibrillation: A Prospective Study in the UK Biobank Cohort. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2025.07.021
Vancouver
Li J, Li G, Ma Z, Sun Z, Shi Y, Lou Z, et al. Life’s Crucial 9, Genetic Susceptibility, and the Risk of Atrial Fibrillation: A Prospective Study in the UK Biobank Cohort. Canadian Journal of Cardiology. 2026. doi:10.1016/j.cjca.2025.07.021
BibTeX
@article{Li2026,
author = {Li, Jianing and Li, Guoxian and Ma, Ze and Sun, Ziqing and Shi, Yujie and Lou, Zexin and Zhao, Hanqing and Sun, Mengtong and Wang, Yu and Han, Qiang and Jiang, Miao and Shen, Yueping},
title = {Life’s Crucial 9, Genetic Susceptibility, and the Risk of Atrial Fibrillation: A Prospective Study in the UK Biobank Cohort},
journal = {Canadian Journal of Cardiology},
year = {2026},
doi = {10.1016/j.cjca.2025.07.021}
}
EUVIMED